Gilead Sciences is acquiring Ouro Medicines in a deal valued at $2.17 billion, adding a BCMAxCD3 T-cell engager to its inflammation and autoimmune pipeline. The transaction is front-loaded with $1.675 billion in cash upfront and contingent payments, with Galapagos expected to remain involved through advanced discussions tied to operating assets and development responsibilities. Gilead’s acquisition centers on OM336 (gamgertamig), currently in phase 1/2 testing for autoimmune hemolytic anemia and immune thrombocytopenia. The structure also reflects a cross-partner approach: Galapagos is expected to pick up development execution while Gilead retains worldwide commercialization rights outside China. The deal marks a deliberate push into antibody-driven “immune reset” strategies for autoimmune indications, reinforcing the broader industry momentum behind BCMA/CD3 immunology targets as differentiated immune-engaging platforms.